JP2016525140A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525140A5
JP2016525140A5 JP2016528540A JP2016528540A JP2016525140A5 JP 2016525140 A5 JP2016525140 A5 JP 2016525140A5 JP 2016528540 A JP2016528540 A JP 2016528540A JP 2016528540 A JP2016528540 A JP 2016528540A JP 2016525140 A5 JP2016525140 A5 JP 2016525140A5
Authority
JP
Japan
Prior art keywords
disorder
flecainide
modafinil
sleep
narcolepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016528540A
Other languages
English (en)
Japanese (ja)
Other versions
JP6192830B2 (ja
JP2016525140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/065975 external-priority patent/WO2015011246A1/en
Publication of JP2016525140A publication Critical patent/JP2016525140A/ja
Publication of JP2016525140A5 publication Critical patent/JP2016525140A5/ja
Application granted granted Critical
Publication of JP6192830B2 publication Critical patent/JP6192830B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016528540A 2013-07-24 2014-07-24 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法 Expired - Fee Related JP6192830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306074 2013-07-24
EP13306074.9 2013-07-24
PCT/EP2014/065975 WO2015011246A1 (en) 2013-07-24 2014-07-24 Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017061022A Division JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Publications (3)

Publication Number Publication Date
JP2016525140A JP2016525140A (ja) 2016-08-22
JP2016525140A5 true JP2016525140A5 (enExample) 2016-12-15
JP6192830B2 JP6192830B2 (ja) 2017-09-06

Family

ID=48900920

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016528540A Expired - Fee Related JP6192830B2 (ja) 2013-07-24 2014-07-24 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2017061022A Expired - Fee Related JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2018233114A Expired - Fee Related JP6694497B2 (ja) 2013-07-24 2018-12-13 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017061022A Expired - Fee Related JP6453931B2 (ja) 2013-07-24 2017-03-27 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2018233114A Expired - Fee Related JP6694497B2 (ja) 2013-07-24 2018-12-13 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法

Country Status (20)

Country Link
US (3) US9750734B2 (enExample)
EP (2) EP3308785A3 (enExample)
JP (3) JP6192830B2 (enExample)
KR (2) KR20170068629A (enExample)
CN (1) CN105579041B (enExample)
AU (1) AU2014295030B2 (enExample)
BR (1) BR112016001446A8 (enExample)
CA (2) CA2919140C (enExample)
DK (1) DK3024458T3 (enExample)
ES (1) ES2661647T3 (enExample)
HR (1) HRP20180487T1 (enExample)
HU (1) HUE037122T2 (enExample)
IL (2) IL243746A (enExample)
MX (2) MX365782B (enExample)
PL (1) PL3024458T3 (enExample)
PT (1) PT3024458T (enExample)
RU (2) RU2661026C2 (enExample)
TR (1) TR201802302T4 (enExample)
WO (1) WO2015011246A1 (enExample)
ZA (1) ZA201601146B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009472A1 (en) * 2015-07-15 2017-01-19 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
EP3781128A4 (en) * 2018-04-16 2022-03-09 Alsar Ltd Partnership COMPOSITIONS AND METHODS FOR THE EXTENDED RELEASE OF FLECAINIDE
US12529704B2 (en) 2018-06-11 2026-01-20 Indiana University Research And Technology Corporation Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
EP3593822A1 (en) 2018-07-13 2020-01-15 Theranexus Therapeutic and diagnostic applications of a new method of monitoring of neuroglial interaction memri)
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11021410B2 (en) * 2018-12-10 2021-06-01 Purdue Research Foundation Layer-wise agglomerated urea granules
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US20220265666A1 (en) * 2019-08-02 2022-08-25 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
CN111018694A (zh) * 2019-12-12 2020-04-17 贵州省欣紫鸿药用辅料有限公司 一种氟卡尼的生产方法
AU2021270308A1 (en) * 2020-05-13 2022-12-15 Akouos, Inc. Compositions and methods for treating GJB2-associated hearing loss
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2022170081A1 (en) * 2021-02-05 2022-08-11 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001253825A (ja) 2000-03-13 2001-09-18 Masahiko Ichimada 帯状疱疹後神経痛用鎮痛剤
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
AU2006318447A1 (en) 2005-11-21 2007-05-31 The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Methods of using small molecule compounds for neuroprotection
KR20100027091A (ko) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20130184462A1 (en) 2010-09-30 2013-07-18 Council Of Scientific & Industrial Research Method for predicting and modeling anti-psychotic activity using virtual screening model
US20130096067A1 (en) 2011-09-14 2013-04-18 Norbert Perrimon Drosophila tumor stem cell model and uses thereof
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor

Similar Documents

Publication Publication Date Title
JP6192830B2 (ja) 抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
JP2016525140A5 (enExample)
TWI787260B (zh) 具有新穎的組成物、組合物及其方法之標靶藥物救援
JP6336592B2 (ja) ヒスタミンh4受容体を介してもたらされた掻痒状態を治療するための医薬組成物
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
RS51464B (sr) Beta-2 adrenoceptorski agonisti za tretman bolesti veznog tkiva kože
TWI409061B (zh) 莫達非尼於縮短抗抑鬱劑效果的開始時間的用途
JP2012508186A (ja) むずむず脚症候群および睡眠障害の治療
K. Semwal et al. Analgesic and antipyretic activities of Gindarudine, a morphine alkaloid from Stephania glabra
Nikoohemmat et al. Intra-accumbal orexinergic system contributes to the stress-induced antinociceptive behaviors in the animal model of acute pain in rats
CN107531670B (zh) 二芳基亚甲基哌啶衍生物及其作为δ阿片受体激动剂的用途
EP1942891B1 (en) Novel combination of drugs as antidepressant
WO2014005720A1 (en) Use of (r)-phenylpiracetam for the treatment of disease-associated fatigue
HK1225278B (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
HK1225278A1 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
Sonawane et al. Evaluation of analgesic and anti-inflammatory activity of Levocetirizine in albino rats
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
KR102280552B1 (ko) 주의 결여·다동성 장애의 예방 및 치료제
EP2845625A1 (en) Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome